The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Academy of Dermatology 2020-08, Vol.83 (2), p.677-679
Hauptverfasser:	Wan, Marilyn T., Shin, Daniel B., Winthrop, Kevin L., Gelfand, Joel M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Betacoronavirus - immunology Biological Products - adverse effects Clinical Decision-Making Clinical Trials, Phase III as Topic Coronavirus Infections - epidemiology Coronavirus Infections - immunology Coronavirus Infections - prevention & control Coronavirus Infections - virology COVID-19 Humans Interleukin-17 - antagonists & inhibitors Interleukin-17 - immunology Interleukin-17 - metabolism Pandemics - prevention & control Pneumonia, Viral - epidemiology Pneumonia, Viral - immunology Pneumonia, Viral - prevention & control Pneumonia, Viral - virology Psoriasis - drug therapy Psoriasis - immunology Risk Assessment SARS-CoV-2 Signal Transduction - drug effects Signal Transduction - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!